Victoza vs. Ozempic

Are Victoza and Ozempic the same drug?

No — they are two different molecules, though both come from Novo Nordisk and belong to the same drug class. Victoza is liraglutide and Ozempic is semaglutide. Both are GLP-1 receptor agonists for type 2 diabetes, but semaglutide is longer-acting, which is why Ozempic is injected once weekly while Victoza is injected once daily [1], [2].

That difference in potency and schedule is the heart of this comparison.

The bigger picture: the GLP-1 brand families

Each molecule is sold under a diabetes brand and a weight-loss brand, which is a common source of confusion:

• Liraglutide → Victoza (type 2 diabetes) and Saxenda (weight management) — both once daily [1].
• Semaglutide → Ozempic (type 2 diabetes), Wegovy (weight management), and Rybelsus (oral tablet) [2].

So Victoza vs. Ozempic is, in effect, liraglutide vs. semaglutide — an older daily GLP-1 against a newer weekly one from the same company.

What is Victoza?

Victoza (liraglutide) is a once-daily injection FDA-approved to improve blood sugar in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. It was one of the first GLP-1 medicines, approved in 2010, and is dosed 0.6 mg, then 1.2 mg, up to 1.8 mg once daily.

Its cardiovascular benefit was established in the LEADER trial, where liraglutide cut major cardiovascular events by 13% versus placebo [1], [4]. Victoza is not approved for weight loss — that is the role of its higher-dose sibling, Saxenda — and it is now available as a generic liraglutide.

What is Ozempic?

Ozempic (semaglutide) is a once-weekly injection FDA-approved for type 2 diabetes, to reduce cardiovascular risk in adults with type 2 diabetes and heart disease, and (as of 2025) to slow chronic kidney disease in type 2 diabetes. It is dosed from 0.25 mg up to 2 mg once weekly.

Semaglutide is a more potent, longer-acting GLP-1 than liraglutide, which is why it works with a single weekly injection. Like Victoza, Ozempic is widely used off-label for weight loss but is not FDA-approved for it — that is the role of Wegovy [2], [5], [6].

How they work

Both mimic GLP-1, a gut hormone that curbs appetite, slows stomach emptying, and triggers insulin when blood sugar is high [1], [2]. They work through the same receptor — the practical difference is duration of action.

Liraglutide clears quickly, so it must be taken every day; semaglutide lasts about a week, allowing a single weekly dose and steadier drug levels. That steadier, longer exposure is part of why semaglutide tends to produce larger reductions in blood sugar and weight [3].

Effectiveness: blood sugar and weight

In the head-to-head SUSTAIN-10 trial, Ozempic outperformed Victoza. Among 577 adults with type 2 diabetes, after 30 weeks once-weekly semaglutide 1.0 mg lowered HbA1c by −1.7% versus −1.0% for once-daily liraglutide 1.2 mg, and reduced body weight by −5.8 kg versus −1.9 kg — both differences statistically significant [3].

More semaglutide users also reached blood-sugar targets and ≥5% weight loss. The comparison used liraglutide's 1.2 mg dose; Victoza can be titrated to 1.8 mg, which narrows but does not erase the gap seen across the GLP-1 evidence.

Beyond the head-to-head numbers, the once-weekly schedule also tends to improve real-world adherence, and better adherence usually translates into better long-term blood-sugar control. Semaglutide's advantage was consistent across the broader SUSTAIN program, not just SUSTAIN-10, which adds weight to the finding.

That said, individual response varies — some people do very well on liraglutide — and the right drug and dose are best matched to your situation by a clinician [1], [2], [3].

What to expect: timeline

Neither drug works overnight. Both start at a low dose and step up to limit nausea, so blood-sugar and any weight changes build over weeks to months rather than days. Liraglutide reaches steady levels quickly because it is taken daily; semaglutide builds to steady levels over the first several weeks of weekly dosing.

Both are long-term treatments for a chronic condition — blood sugar drifts back up if you stop — so they are meant to be taken continuously and supervised over the long run [1], [2].

Daily vs. weekly: convenience

This is a real, practical difference. Victoza requires an injection every day; Ozempic requires one per week. For many people, a single weekly injection is easier to remember and stick with over the long term, which can translate into better real-world results.

Victoza's daily schedule does allow more gradual, flexible adjustment, and a daily routine suits some people better — but convenience is one of the main reasons newer weekly GLP-1s have largely overtaken daily ones [1], [2].

Heart and kidney protection

Both have proven cardiovascular benefit — but Ozempic adds kidney protection. In LEADER, Victoza (liraglutide) reduced major cardiovascular events by 13% in people with type 2 diabetes at high cardiovascular risk; in SUSTAIN-6, Ozempic (semaglutide) reduced them by 26% [4], [5].

Ozempic is also FDA-approved, based on the FLOW trial, to slow kidney-disease progression in type 2 diabetes — an indication Victoza does not carry [2], [6]. For someone with diabetes plus heart or kidney disease, those proven outcomes can outweigh small differences in blood-sugar numbers.

Dosing & administration

Both are subcutaneous injections in prefilled pens, started low and titrated up to limit nausea [1], [2].

Victoza dosing

0.6 mg daily for 1 week → 1.2 mg → 1.8 mg maximum, once daily [1].

Ozempic dosing

0.25 mg weekly (start) → 0.5 → 1 → 2 mg maximum, once weekly [2].

Side effects & safety

Side effects are similar for both because they act on the same GLP-1 pathway — predominantly gastrointestinal, usually mild-to-moderate, and worst when starting or increasing the dose [1], [2].

Serious risks & boxed warning

Both carry a boxed warning for thyroid C-cell tumors and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 [1], [2]. Both can also cause pancreatitis, gallbladder disease, acute kidney injury from dehydration, and low blood sugar when combined with insulin or a sulfonylurea [1], [2].

Who should not take these (and key cautions)

Avoid either drug with a personal or family history of MTC or MEN 2, or a prior serious reaction to it [1], [2]. Use caution with a history of pancreatitis or gallbladder disease.

Both are GLP-1 medicines that clear from the body over days to a week, so discuss pregnancy plans with your clinician — semaglutide in particular should be stopped well before a planned pregnancy [2]. Tell your clinician your full history before starting.

Cost & insurance coverage

Cost is one area where Victoza can win. Because liraglutide is now available as a generic, Victoza (or generic liraglutide) can be less expensive than Ozempic, whose brand list price runs around $1,000 a month before insurance [1], [2].

As always, what you actually pay depends on your insurance coverage and any manufacturer savings program, and a supervised medical program like JumpstartMD's can help you weigh cost against effectiveness.

A note on compounded versions: compounded GLP-1 medications can be a lower-cost route, and the rules around them shifted as the recent shortages resolved [7]. Quality and physician oversight vary by source, so a compounded option should come from a licensed, supervised medical program using a reputable compounding pharmacy — not an anonymous online seller.

JumpstartMD prescribes and supervises these medications, including compounded options where appropriate.

Can you switch between them?

Yes — switching from Victoza to Ozempic is common and is done under medical supervision. People often move to Ozempic for the weekly schedule and stronger effect. Because they are different molecules, a clinician starts Ozempic at its own introductory dose rather than matching milligrams, and manages side effects through the titration.

You should not take both at once — they are the same class of drug [2].

Which is right for you?

• You want the strongest blood-sugar and weight effect, or a weekly schedule → Ozempic outperformed Victoza head-to-head and is dosed once weekly [3].
• Cost is the priority → generic liraglutide (Victoza) may be cheaper, and it still carries proven cardiovascular benefit [1], [4].
• You have kidney disease with diabetes → Ozempic has the FDA-approved kidney-protection indication that Victoza lacks [2], [6].

The right choice depends on your diabetes control, other conditions, insurance, and how you feel about a daily versus weekly injection — exactly what a supervised consultation sorts out. JumpstartMD physicians prescribe and manage both Victoza and Ozempic, including dose titration and side-effect management.